Tu Z - Search Results

1

A Signature of N⁶-methyladenosine Regulator-Related Genes Predicts Prognoses and Immune Responses for Head and Neck Squamous Cell Carcinoma.

Chen J, Lu T, Zhong F, Lv Q, Fang M, Tu Z, Ji Y, Li J, Gong X. Chen J, et al. Among authors: tu z. Front Immunol. 2022 Feb 3;13:809872. doi: 10.3389/fimmu.2022.809872. eCollection 2022. Front Immunol. 2022. PMID: 35185897 Free PMC article.

2

High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell Carcinoma.

Lu T, Zheng Y, Gong X, Lv Q, Chen J, Tu Z, Lin S, Pan J, Guo Q, Li J. Lu T, et al. Among authors: tu z. Front Oncol. 2021 Mar 8;11:608842. doi: 10.3389/fonc.2021.608842. eCollection 2021. Front Oncol. 2021. PMID: 33763352 Free PMC article.

3

SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma.

Lu T, Chen Y, Gong X, Guo Q, Lin C, Luo Q, Tu Z, Pan J, Li J. Lu T, et al. Among authors: tu z. Cancer Med. 2021 Nov;10(21):7847-7862. doi: 10.1002/cam4.4301. Epub 2021 Sep 30. Cancer Med. 2021. PMID: 34590792 Free PMC article.

4

Is a high-risk clinical target volume required? Evaluation of the dosimetric feasibility based on T staging.

Yuan X, Yan C, Peng S, Chen Z, Lu T, Gong Q, Qiu Y, Xiong W, Ao F, Li G, Li J, Tu Z. Yuan X, et al. Among authors: tu z. Front Oncol. 2022 Sep 2;12:800400. doi: 10.3389/fonc.2022.800400. eCollection 2022. Front Oncol. 2022. PMID: 36119501 Free PMC article.

5

CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis.

Tu Z, Chen Q, Zhang JT, Jiang X, Xia Y, Chan HC. Tu Z, et al. Oncotarget. 2016 Nov 22;7(47):76955-76965. doi: 10.18632/oncotarget.12762. Oncotarget. 2016. PMID: 27769067 Free PMC article.

6

ZBTB7A functioned as an oncogene in colorectal cancer.

Wang L, Zhang MX, Zhang MF, Tu ZW. Wang L, et al. BMC Gastroenterol. 2020 Nov 9;20(1):370. doi: 10.1186/s12876-020-01456-z. BMC Gastroenterol. 2020. PMID: 33167891 Free PMC article.

7

LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma.

Zhang MX, Wang L, Zeng L, Tu ZW. Zhang MX, et al. Front Oncol. 2021 Feb 2;10:605777. doi: 10.3389/fonc.2020.605777. eCollection 2020. Front Oncol. 2021. PMID: 33604288 Free PMC article.

8

The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.

Zou R, Yuan JJ, Li Q, Ding JW, Liao B, Tu ZW, Hu RH, Gong D, Hu JL, Zeng L. Zou R, et al. Front Oncol. 2021 Feb 26;10:619625. doi: 10.3389/fonc.2020.619625. eCollection 2020. Front Oncol. 2021. PMID: 33791194 Free PMC article.

9

Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma.

Zhang MX, Wang L, Zeng L, Tu ZW. Zhang MX, et al. Front Oncol. 2021 Mar 18;11:670714. doi: 10.3389/fonc.2021.670714. eCollection 2021. Front Oncol. 2021. PMID: 33816321 Free PMC article.

10

Institutionally validated nomogram predicting prognosis for older patients with nonmetastatic nasopharyngeal carcinoma.

Yan C, Tu Z, Zhang Z, Ouyang X, Li D, Peng S, Zhong J. Yan C, et al. Among authors: tu z. Future Oncol. 2022 May;18(15):1829-1838. doi: 10.2217/fon-2021-1121. Epub 2022 Feb 18. Future Oncol. 2022. PMID: 35179075

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,419 results

Search Page

Filters